A serological assay to detect SARS-CoV-2 seroconversion in humans
Open Access
- 18 March 2020
- preprint content
- other
- Published by Cold Spring Harbor Laboratory
Abstract
SARS-Cov-2 (severe acute respiratory disease coronavirus 2), which causes Coronavirus Disease 2019 (COVID19) was first detected in China in late 2019 and has since then caused a global pandemic. While molecular assays to directly detect the viral genetic material are available for the diagnosis of acute infection, we currently lack serological assays suitable to specifically detect SARS-CoV-2 antibodies. Here we describe serological enzyme-linked immunosorbent assays (ELISA) that we developed using recombinant antigens derived from the spike protein of SARS-CoV-2. Using negative control samples representing pre-COVID 19 background immunity in the general adult population as well as samples from COVID19 patients, we demonstrate that these assays are sensitive and specific, allowing for screening and identification of COVID19 seroconverters using human plasma/serum as early as two days post COVID19 symptoms onset. Importantly, these assays do not require handling of infectious virus, can be adjusted to detect different antibody types and are amendable to scaling. Such serological assays are of critical importance to determine seroprevalence in a given population, define previous exposure and identify highly reactive human donors for the generation of convalescent serum as therapeutic. Sensitive and specific identification of coronavirus SARS-Cov-2 antibody titers may, in the future, also support screening of health care workers to identify those who are already immune and can be deployed to care for infected patients minimizing the risk of viral spread to colleagues and other patients.Keywords
This publication has 28 references indexed in Scilit:
- Pre-fusion structure of a human coronavirus spike proteinNature, 2016
- Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in HumansmBio, 2016
- Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression SystemJournal of Visualized Experiments, 2013
- A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin SubstratesPLOS ONE, 2012
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptorProceedings of the National Academy of Sciences, 2009
- Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape MutantsPLoS Medicine, 2006
- Two‐Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory SyndromeThe Journal of Infectious Diseases, 2006
- Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with ReceptorScience, 2005
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990